Chemoperfusion as a Minimal Invasive Treatment for Pleural Mesotheliomas

SST16-08

Chemoperfusion as a Minimal Invasive Treatment for Pleural Mesotheliomas

Scientific Formal (Paper) Presentations

Presented on December 3, 2010
Presented as part of SST16: Vascular/Interventional (Oncologic Interventions in the Kidney, Lung, and beyond: VIR—Oncology)

Thomas Josef Vogl MD, Presenter: Nothing to Disclose

Sebastian Lindemayr, Abstract Co-Author: Nothing to Disclose

To evaluate tumor response with volumetric assessment for tumor sizes after treatment of non resectable pleural mesotheliomas with chemoperfusion in palliative intention.

Between 2007 and 2010, 46 patients suffering from unresectable pleural mesotheliomas were treated with chemoperfusion. In 7 patients follow-up was not evaluable, thus these patients were classified “drop out”. Treatment was repeated between 1 and 7 times with a mean of 2.9 sessions. Mean age was 64.0 years, male to female ratio was 9/37. Tumor-feeding arteries were selectively probed after puncture of the femoral artery and 5 to 10 ml of Lipiodol as well as 5 to 10 mg of Mitomycin C were administered during balloon protection. At 4-week intervals, diagnosis and follow-up were accomplished by using unenhanced as well as contrast-enhanced computed tomography.

All patients tolerated the repeated treatments without adverse effects. Neither complications nor influences on labaratory parameters were observed. In 23.1% (n=9) of treated tumors, tumor volume was resolved to 282.9 ml on average. In 46.2% (n=18) tumor volume remained unchanged and in another 30.7% (n=12) volume increased to 442.7 ml on average. According to the RECIST criteria “partial response” was recorded in 9 cases, “stable disease” in 18 cases and “progressive disease” in another 12 cases. Mean survival time was calculated 514.5 days (according to Kaplan-Meyer).

According to these findings, chemoperfusion might be a well tolerated procedure for the palliative treatment of non resectable pleural mesotheliomas.

Chemoperfusion is a relevant palliative treatment option in patients with non resectable pleural mesotheliomas.

Vogl, T, Lindemayr, S, Chemoperfusion as a Minimal Invasive Treatment for Pleural Mesotheliomas. Radiological Society of North America 2010 Scientific Assembly and Annual Meeting, November 28 - December 3, 2010 ,Chicago IL. http://archive.rsna.org/2010/9007951.html